Vifor Pharma

CompanySwitzerland

Vifor Pharma develops one asset, in phase 2 (PA21 in chronic kidney disease). Mostly small molecule; based in Switzerland.

Assets
1
Furthest
Phase 2
Trials
4
Signals
0

Pipeline

1

  • PA21

    Phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease

    Phase 2Small moleculechronic kidney disease

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms1
  • Trials7
  • Similar companies6

Updated 7 Oct 2026 · 10 sources

Intelligence